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Abstract
The incidence of Autism Spectrum Disorder (ASD) in 8-year old children is 1 in 59. This
increased from approximately 1 in 150 reported in 2000-2002 (Baio et al., 2014). Autism
includes deficits in social emotional reciprocity, non-verbal communication for social
interactions, developing and maintaining relationships and in some cases, hyperactivity response
to sensory input. Hyperactivity is a shared behavior with ASD and Attention Deficit
Hyperactivity Disorder (ADHD). Medications such as Methylphenidate (MPH) and α 2-a
adrenergic receptor agonists are used to modify hyperactivity behavior in ADHD and thus have
been used as management in ASD. A review of literature was done to evaluate the use of
medications typically used for ADHD in the use of ASD. The databases searched included
PubMED, PsycINFO, Cochrane, and Clinical Key. Current findings are inconclusive as to
whether these medications are as effective at treating impulsivity-hyperactivity behaviors in
children with ASD.
Keywords: ASD, ADHD, PDD-NOS, Asperger syndrome, autistic disorder, Hyperactivity,
Stimulants, MPH, Guanfacine, Clonidine
Pharmacotherapy for Impulsivity-Hyperactivity Behaviors in Autism Spectrum Disorder
Introduction
According to the DSM-V, Autism Spectrum Disorder (ASD) is defined as a range of
behaviors that include deficits in social emotional reciprocity, non-verbal communication for
social interactions, developing and maintaining relationships and in some cases, hyperactivity
response to sensory input. These deficits often lead to impaired functioning in school and with
peers. Attention Deficit Hyperactive Disorder (ADHD) is a brain disorder that is characterized
by inattentiveness, hyperactivity, and impulsive behaviors. These symptoms interfere with the
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quality of social, academic and occupational aspects of life (American Psychiatric Association,
2013). Children with ASD and ADHD often share a similar behavior profile. These behaviors
include hyperactivity, oppositional behavior, inattentiveness, and impulsiveness (Konst, Matson,
Goldin, Rieske, 2014). Both psychostimulants such as methylphenidate (MPH) and nonstimulant medications such as α 2-a adrenergic receptor agonists (guanfacine and clonidine) are
used in ASD and ADHD to treat the symptoms of impulsivity-hyperactivity behaviors. This
literature review includes studies comparing the effectiveness of these medications at improving
behaviors in both children with ASD and ADHD as well as look at the compliance rates of these
medications in relation to parental choice for discontinuation due to side effect profiles.
Statement of the Problem
ASD and ADHD behaviors interfere negatively with daily living for children, peers,
teachers and parents/caregivers, which makes day to day life difficult for both the child and
others involved. Pharmacotherapy is often used to help manage these behaviors and to make
daily living more manageable for the child and those around them. There are a few classes of
drugs used to help with ADHD, including psychostimulants, non-stimulants, and psychotropic
drugs. The first line pharmacotherapy for children with ADHD is typically a stimulant. Due to
similarities in behavior profiles, psychostimulants are used off-label for impulsivityhyperactivity behaviors in children with ASD without a comorbid diagnosis of ADHD. Research
needs to be done to investigate the effectiveness of these medications in children with ASD to
help explore further management of these behaviors.
Research Questions
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In children with ASD, are psychostimulants, such as MPH as effective at reducing
impulsivity-hyperactivity behaviors as compared to children with ADHD according to teacher
and parent reports?
In children with ASD, are α 2-a adrenergic receptor agonists, such as clonidine and
guanfacine, more effective at reducing impulsivity-hyperactivity behaviors as compared to
psychostimulants such as MPH, according to teacher and parent reports?
Are the rates of discontinuation of pharmacotherapy in children with ASD higher in
treatment with MPH vs clonidine or guanfacine?
Research Methods
To prepare for this literature review, a search of internet database resources was
conducted. The databases searched included PubMED, PsycINFO, Cochrane, and Clinical Key.
Articles were selected that evaluated the efficacy of psychostimulants and α 2-a adrenergic
receptor agonists in the pediatric population with the sole diagnosis of ASD. Participants in these
studies were not diagnosed with co-morbid disorders such as ADHD, epilepsy, Tourette
syndrome, or other developmental pathophysiology that could explain etiology of behaviors.
Due to the changing verbiage and diagnostic criteria from DSM-III through DSM-V, the search
terms were expanded to not only include Autism Spectrum Disorder, but also: Autistic Disorder,
Asperger’s Syndrome, and Pervasive Development Disorder Not Otherwise Specified. Studies
were excluded if the subjects had a diagnosis of both ADHD and ASD, as this literature review
was conducted to evaluate the off-label use of pharmacotherapy in ASD without comorbid
ADHD. An initial period of 10 years from 2008-2018 was used as a time-frame, however due to
limited studies conducted involving the ASD population, this was expanded to a 30-year time
frame of 1988-2018.
Review of Literature
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Methylphenidate as a treatment for impulsivity-hyperactivity in ASD
Handen, Johnson and Lubetsky (2000) completed a trial with MPH to treat ADHD-like
symptoms in children with Pervasive Development Disorder (PDD)/Autism. The goal of this
trial was to further investigate the safety and efficacy of the use of MPH in children with autism.
Thirteen children with autism participated in this trial. A double-blind, placebo-controlled,
crossover trial was conducted with 0.3 and 0.6 mg/kg of MPH as compared to placebo dose. The
low dose, high dose and placebo were each given for 7 consecutive days. At the end of these 7
days, the teachers or program staff were given behavioral and side effect questionnaires to
complete. Some subjects resided in inpatient or residential treatment facilities, therefore parent
questionnaires were not used in this trial. Eight of the thirteen children were found to be
responders based on a minimum of a 50% decrease in behaviors according to the Teacher
Conners’ Hyperactivity Index. MPH was found to be beneficial at treating hyperactivity in
autism according to the Conner’s Teacher scale (CTQ) (p = .000), Iowa Conners’ Teacher Rating
Scale (p = .004), and the Aberrant Behavior Checklist (ABC) (p = .003) (Handen, Johnson, &
Lubestky, 2000).
As with related trials, this study had a low number of subjects enrolled. At only 13
participants, this makes it difficult to show continuity of response across a population. The fact
that the parent input was not factored in is another weakness of this study. Another wellcontrolled study with larger sample sizes will need to be done to ascertain if this study can be
replicated across a larger population. Parent input also needs to be assessed as home behaviors
were not analyzed with this study.
As with previously discussed trials, the goal of the study by Quintana et al. (1995) was to
evaluate the efficacy of MPH in the treatment of impulsivity, short attention span and
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hyperactivity in children with autism. It was the first reported study that used a double-blind
method. Ten children ages 7-11 were chosen to participate in this study. This study took place at
Children’s Day Hospital at the New York State Psychiatric Institute. The children were observed
over the duration of the 6-week study. The first 2 weeks were used to evaluate each subject’s
baseline behaviors. On the third week, subjects were randomly selected to receive either 10 mg
of MPH or placebo in the morning and at noon. The next week, they were given either 20 mg of
MPH or placebo in the morning and at noon. The last 2 weeks, children were crossed over and
children who were receiving placebo were given active MPH, and children receiving MPH were
given placebo according to the same schedule. It was found that MPH was superior to placebo at
reducing hyperactivity according to the CTQ and ABC. MPH vs placebo and MPH vs baseline
evaluations of CTQ (p = .02 and p = .006 respectively) and ABC (p = .04 and p = .003
respectively) showed statistically significant improvement in behaviors. The investigators, the
children and parents were all blind to whether they were taking the active medication or placebo,
as well as the dose the children were receiving.
This trial was limited by the smaller number of only 10 children. It was also located
solely in the New York area, and thus population demographics were limited to this area. The
Conners’ Parent Questionnaire (CPQ) showed no statistical improvement in hyperactivity of
MPH versus placebo. This could be that the CPQ was filled out independently by parents on
different days and times than that of the CTQ. The CPQ was also based off children’s behavior
in their home environment, in which the psychiatrists did not assess the children. The trial
duration was only 6 weeks. As previously discussed, due to the nature of stereotypical autism
behaviors, a longer trial would be needed to make sure the subjects were fully acclimated to the
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schedule of the trial. Further trials would need to be completed with larger subject size to
confirm the results of this trial.
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005)
conducted a trial with the goal of determining efficacy as well as safety of methylphenidate in
children with pervasive developmental disorders and hyperactivity according to DSM-IV
criteria. The trial was conducted in a double-blind, placebo-controlled, crossover trial followed
by open label continuation. 117 subjects were assessed. Of these, only 66 were found to be
eligible to continue after passing the one-week test dose phase. MPH was found to be statistically
superior at all doses when compared to the placebo according to the ABC hyperactivity subscale
score as rated by both teacher (p = .009) and parent (p < .001). Of the original 66 subjects that
were found to be eligible, 35 of these were enrolled in the open label continuation. 32 of the 35
completed the study. It was found that the MPH was consistently effective throughout the 8week open-label continuation. RUPP (2005) reported, “Our response rate of 49% is less than the
previously described response rates of 70% to 80% seen in typically developing children with
ADHD” (p.1272). Therefore, although it was found that approximately half of children with
PDD and hyperactivity achieved a response to MPH, the rate of response was lower than that of
use with children with ADHD (RUPP, 2005).
There were some limitations to this trial. The acute response to MPH was tested, but the
long-term response was not. This study also did not include high doses of MPH owing to the
frequency of adverse effects. Therefore, those that did not achieve a response to MPH could have
required higher doses to achieve said response. The use of MPH in children with ASD receiving
pharmacotherapy with other forms of medication was also not included in this study. The
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children receiving psychopharmacotherapy with other classes could have achieved improvement
in hyperactivity if cotreated with MPH.
Methylphenidate as a treatment for impulsivity-hyperactivity in ADHD
In this study conducted by Greenhill, Findling and Swanson (2002), the efficacy of MPH
was evaluated against placebo. This was a multisite, randomized, placebo-controlled crossover
trial that included 314 subjects aged 6-16 with a diagnosis of ADHD according to the DSM-IV
criteria. This study was conducted with a one-week washout period prior to the start of the trial
to ensure elimination of any drug interactions as well as to eliminate placebo responders. After
the washout period, subjects were evaluated to obtain a baseline assessment. This was then
followed by a 3-week randomized, double-blind phase. It was found that there was a significant
improvement with the active dose of MPH over placebo according to Clinical Global
Impressions (CGI) scores. 81% were deemed responders to MPH versus 50% deemed responders
to placebo. In addition, according to CPQ, MPH proved superior to placebo at optimal dosage (p
< .001). This finding was also true according to CTQ (p < .001) (Greenhill, Findling & Swanson,
2002).
Limitations were found in this study to include the relatively short duration of only three
weeks. The long-term efficacy of MPH and continued response could not be evaluated. There
was also a potential for bias within the placebo group as parents knew the clinician could
increase the dose of medication based on the ratings of the previous week. In knowing this, they
could have assumed their child was receiving the active dose of MPH thus increasing a perceived
placebo response. By excluding both placebo responders as well as those previously nonresponsive to treatment with MPH, this skewed the results that may have been found across the
generalized population of those diagnosed with ADHD.
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The goal of the study conducted by Wilens et al., (2006) was to evaluate the efficacy and
safety of MPH versus placebo in the treatment of ADHD. This trial included 220 subjects
between the ages of 13-17 years old that had a diagnosis of ADHD according to DSM-IV
criteria. The study was initiated by a 1-week washout period where all other medications used for
the treatment of ADHD were discontinued. This was then followed by an evaluation to obtain a
baseline assessment. After the baseline assessment was completed, subjects were enrolled in a
phase to titrate the dose of MPH to their individual optimal dose. This process took up to 4
weeks. Subjects who were able to successfully complete the titration phase were then
randomized into groups according to their dosage level in the double-blinded portion of the trial.
This phase lasted 4 weeks and was followed by an 8-week open-label follow-up phase. Twentyseven (12%) of the 220 subjects enrolled withdrew from the titration dose phase and did not
continue to the double-blind portion. Furthermore, 11 (5%) of subjects did not meet the
minimum requirements at the maximum dose of 72 mg per day and were not allowed to continue
with this trial. Of the 182 subjects that completed the titration phase, 177 of them were
randomized into double-blind groups to either receive placebo or MPH. Treatment with MPH
was found to be statistically superior in efficacy than treatment with placebo. 52% of subjects in
the MPH group achieved some benefit from the medication according to the CGI improvement
subscale (p = .01). In addition, the Attention Deficit Hyperactivity Disorder Rating Scale
(ADHD-RS) (p = .03), Global Assessment of Effectiveness (p = .004) and Conners-Wells
Adolescent Self-Report Symptoms Scale (p = .007) all indicated benefit from MPH over
placebo.
Because this study excluded previous non-responders to MPH and those who could not
tolerate MPH dosing in the titration phase, the results cannot be applied to the global population
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of those diagnosed with ADHD. The exclusion of subjects that could not tolerate the titration
phase also leads to a possibility of a falsely lowered number of reported adverse effects as well
as rates of discontinuation due to these side effects.
α 2-a receptor agonists as treatment for impulsivity-hyperactivity in ASD
Clonidine has been found to be effective at improving attention and decreasing
impulsivity and hyperactivity in children with ADHD. The study by Jaselskis, Cook, Fletcher
and Leventhal (1992) was created to determine the efficacy of reducing hyperactivity and
impulsivity in young boys with autistic disorder according to DSM-III-R criteria. Eight male
children with ages ranging from 5-11 were recruited to participate in this study. All were deemed
to have autistic disorder according the DSM-III-R criteria. All subjects were reported to have
hyperactivity, distractibility and impulsive behaviors that affected their function in the classroom
and at home. A 4-week, medication free period was required by all participants prior to starting
the trial. The subjects were then randomly selected to receive either placebo or the active
medication of clonidine. Active medication or placebo tablets were identical in appearance and
were given three times per day. Medication or placebo tablets were titrated up over the first two
weeks to a dose of 4-10 mg/kg per day. During week seven subjects’ doses were tapered down.
The subjects were then crossed over to the alternate medication and weeks 8-13 were conducted
the same as the first 7 weeks. According to the CPQ, clonidine showed significant improvement
over placebo (p = .03). According to the teachers’ rating on the ABC factors of irritability and
hyperactivity, there was significant improvement with clonidine vs placebo (p = .01, and p = .03,
respectively). None of the clinicians reported a statistically significant difference comparing
placebo to clonidine. Six of the eight subjects opted to continue an open label phase of clonidine
for 6 weeks post trial. All subjects reported continued decrease in hyperactivity and/or irritability
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throughout this 6-week period. Of the six that continued, four discontinued clonidine after
current dosage became ineffective and an increase in medication dose led to an increase in side
effects (Jaselskis, Cook, Fletcher & Leventhal, 1992). “Although this study revealed a modest
therapeutic effect of clonidine in the acute management of autistic children with concomitant
hyperactivity, inattention and distractibility, side effects of hypotension and drowsiness make it
clear that its role in the management of these symptoms in children with autistic disorder may be
limited” (Jaselskis et al., 1992, p. 326).
This study was reliable in that it was a double-blind, placebo-controlled trial. It fell short
in that it only studied males, and the subject group was small with only eight participants. The
clinicians’ evaluations were done in a small office. Children with ASD thrive in familiar
environments. Due to the location and nature of the clinicians’ evaluations, this could have
contributed to the fact that clinicians did not report a statistically significant improvement in
behaviors with clonidine over placebo.
As with the study by Jaselskis et al. (1992), the goal of this trial conducted by
Fankahuser, Karumanchi, German, Yates and Karumanchi (1992) was to evaluate the therapeutic
effect of transdermal clonidine in autism regarding reducing hyperarousal and hyperactivity
behaviors. Subjects for this trial were recruited via television advertisement as well as letters sent
to physicians and parents. Nine males diagnosed with autism according to the DSM-III-R criteria
were selected to participate in the study. The age range was from 5-33 years of age. Subjects
were randomly assigned to either receive a 4-week treatment of clonidine or placebo, both via
transdermal patch. After the 4-week treatment period, the subjects underwent a 2-week washout
period. They were then crossed over to the alternate therapy for another 4-week treatment period.
Each subject had to be free from medication for 2 weeks prior to starting the trial. Dosing of
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clonidine was titrated according to individual weight. Subjects were evaluated by the raters seven
times over the course of the trial. This included the assessment completed prior to the start of the
trial which determined baseline behaviors. Each subject’s parents also completed evaluations of
their child’s behavior and any observed side effects of the medication. Results showed a
significant improvement of clonidine over placebo treatment according to CGI global
improvement ratings (p<.001). Six of the nine (66.7%) subjects were rated as “much improved”
or “very much improved” according to Clinical Global Impressions-Improvement (CGI-I).
Parents reported overall improvement since starting the study according to the Parent Global
Ratings (p = .0475). Parents also reported that clonidine had a calming effect on their
child/participant, which they felt contributed to reduced hyperarousal, hyperactivity and
inattention. An overall improvement was seen in seven out of the nine participants. Two of the
participants did not complete the study (Fankahuser, Karumanchi, German, Yates &
Karumanchi, 1992).
This trial has good reliability of results based off the double-blind, placebo-controlled
model used. It was free from unconscious bias as well and investigator bias. The downfall of this
trial was the small group of individuals studied. The age group was also a wide range, therefore
not taking in to account pediatric vs. adult reaction to medications as well as the differing daily
environments in these age groups. Due to the small group of subjects as well as the vast age
range, the results cannot be clinically applied to the autism population and, more specifically, the
pediatric population. This being an all-male study can also be considered a downfall. This is
likely related to the fact that autism has a higher incidence in males than females. Further clinical
trials are needed to validate the results.
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Handen, Sahl and Harden (2008) conducted a study with the purpose of trialing
guanfacine as a treatment for inattention and hyperactivity symptoms in children with autism.
Children were chosen for this trial based off the DSM-IV criteria for autism as well as presenting
ADHD-like symptoms such as hyperactivity. Subject also had to score 15 points or higher on the
Conner’s Parent and/or Teacher Hyperactivity Index. A total of 11 subjects were enrolled in the
study ranging from ages 5-9. Each child was assessed using the ABC, CGI, and a side effects
scale. Assessments were completed at baseline, as well as completed at subsequent clinic
appointments. The subjects were randomly assigned medications in a double-blind, placebocontrolled trial. The first group was randomly assigned to begin with guanfacine given 3 times
daily. The dose was titrated to a maximum of 30 mg/day over a 19-day period, then each subject
remained on the higher dose for eight consecutive days. The subjects then went through a 6-day
washout followed by an 8-day placebo phase. The other group was given a placebo dose three
times per day for eight days. After eight days, they were changed to guanfacine three times daily
and titrated up to a maximum dose of 3 mg/day. This was then followed by eight consecutive
days of the higher dose of guanfacine followed by a 6-day taper. The results found that five
(45%) of the eleven participants were responders based on a 50% or great reduction in their ABC
Hyperactivity score between guanfacine and placebo doses. In addition, the Conner’s Global
Rating of Impairment (p = .005), Parent ABC Hyperactivity subscale (p = .025), and Teacher
ABC Hyperactivity subscale (p = .005) were found to have statistically significant difference in
scores between drug and placebo groups. This indicates an improvement of symptoms while on
the active dose of medication versus placebo (Handen, Sahl & Harden, 2008).
As with other similar trials, this study has a relatively small subject group. Only 11
children participated in this trial making it statistically difficult to apply the results of the trial
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across the autism population. This was, however, a double-blind, placebo-controlled study
which helped eliminate bias on the part of both the parent/teacher as well as the clinician and
participants. The subjects also included a wide range of cognitive functioning. Therefore,
cognitive functioning could not be ruled out or in as a factor in medication efficacy. This sample
of participants also included children both with intellectual disability and autism. As a result, this
study was not exclusive to autism singularly. Some of the data was incomplete due to one parent
and one teacher not returning a questionnaire due to absences. When this happened, the teacher
or parent questionnaire (whichever one was completed) was used to represent both teacher and
parent questionnaires. This left room for incomplete evaluation of efficacy, but overall results
remained intact.
The research for this article by Posey, Puntney, Sasher, Kem and Mcdougle (2004) took
place at the Autism/Pervasive Developmental Disorders Clinic at the James Whitcomb Riley
Hospital for Children. The goal of this study was to determine the efficacy of guanfacine in
children with pervasive developmental disorders according to DSM-IV criteria that showed traits
of hyperactivity and inattention. A chart review of 704 subjects that were treated with guanfacine
were reviewed by two board certified child and adolescent psychiatrists to determine eligibility.
All subjects who had been treated with guanfacine between 1997 and 2001 were included in the
study. A total of 80 subjects (10 females and 70 males) were ultimately included in the study. 19
of the 80 subjects (23.8%) were deemed as “responder” based on the CGI global improvement
score. There was a small, but statistically significant improvement in CGI scores throughout the
entire group (p < .001). A decrease in hyperactivity was seen in 36.7% of participants. Severity
of the disorder played a role in the responsiveness. Subjects with Asperger’s or Pervasive
Development Disorder- Not Otherwise Specified (PDD-NOS) showed a greater rate of global
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response according to CGI-I score than those with autistic disorder (p=.009). According to Posey
et al., “For most subjects, guanfacine treatment was not effective” (p. 239). It was concluded that
of those deemed a responder to guanfacine, it was found to be well tolerated and modestly
effective at treating ADHD-like symptoms (Posey, Puntney, Sasher, Kem & Mcdougle, 2004).
This is a retrospective chart review. In analyzing the data in this study, subjective data
was left up to interpretation of the psychiatrists. Due to not actively being involved in observing
response, the CGI global improvement score was based off documentation in the charts. This
score was thus dependent on complete and accurate charting at the time of review. Furthermore,
this study was not blinded. Subjects were aware of their medication treatment plan (open-label)
as such they were subject to unconscious bias based off their individual expectations of
medication therapy outcomes.
Scahill et al. (2006) conducted a study that was a multisite, 8-week open-label trial of
guanfacine. The goal of this study was to collect prospective pilot date on the safety and efficacy
of guanfacine for the treatment of hyperactivity in children with PDD as identified by DSM-IVTR criteria, otherwise known as Autism Spectrum Disorder now classified by DSM-V. 25
children ranging in ages from 5-14 participated in this study. Guanfacine doses were assigned
according to weight. Children weighing <25kg were given an initial dose of 0.25mg at bedtime.
This was increased to 0.25mg BID on day 4. Doses were increased by 0.25 mg every four days,
up to a maximum dose of 3.5mg/day, given in TID dosing. Children weighing >25 kg were
started on 0.5 mg of guanfacine at bedtime and then increased in similar fashion by 0.5 mg
increments to a maximum dose of 5 mg/day, given TID. Medication titrations were allowed at
any time as needed according to experienced side effects. Hyperactivity declined by 40% from
baseline according to parent-rated ABC subscale (p<.0001). The teacher-rated subscale showed

PHARMACOTHERAPY FOR AUTISM

20

a 25% decrease in hyperactivity (p<.01). According to teacher and parent-rated change on the
Swanson, Nolan and Pelham Questionnaire (SNAP-IV ), the clinician rated that 12 out of 25
(48%) subjects were “much improved” or “very much improved”. Parent SNAP-IV scores for
hyperactivity went down from 35.5 at baseline to 22.7 at endpoint, for a 36% decrease in scores
(p<.0001). Teacher SNAP-IV scored for hyperactivity also decreased considerably from baseline
by 20% (p=.01) Two of the children were removed from the study due to lack of efficacy, and
three withdrew early due to irritability. Overall, guanfacine was shown to be effective at
reducing hyperactivity by 39% in children with PDD when looking at all measurement used
(Scahill et al., 2006).
This study falls short in that it was open-label, and therefore open to bias by parent,
teacher and clinician. Furthermore, there was no placebo-control, and therefore the results
cannot be adjusted to account for bias. This is also a relatively small study of only 25
participants, and it is unknown if similar results would be reported in another trial with a larger
sample size. Due to these short-comings, it is difficulty to apply these findings to clinical
practice. A large-scale, controlled study would need to be conducted to validate the results.
This clinical trial was conducted by the Research Units on Pediatric Psychopharmacology
Autism Network. The goal of this trial by Scahill, et al. (2015) was to study the efficacy of
extended-release guanfacine in children with autism that showed ADHD-like behaviors. In the
previous study discussed by Scahill et al. (2005), it was found that a large-scale controlled study
would need to be conducted to add validity to their findings. This study is a step towards a
larger-scale study. This was a five-site randomized, double blinded placebo controlled clinical
trial. A multidisciplinary team at each site conducted the research to include screening, baseline,
and follow-up assessments. All subjects were between ages 5 and 14 years old. The subjects
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were diagnosed with autistic disorder (AD), Asperger’s syndrome (AS), or pervasive disorder
not otherwise specified (PDD-NOS) according to DSM-IV criteria. The behaviors of
hyperactivity, impulsiveness, and distractibility were looked at most closely in relation to
reducing these behaviors with medication management. These subjects were treated with
guanfacine for an 8-week period. Assessments were done at baseline and at the end of the 8week trial. 81 children were screened, and eligible subjects were randomly assigned either
extended-release guanfacine or placebo. It was found that guanfacine was superior to placebo
according to the Aberrant Behavior Checklist-hyperactivity subscale (p<0.001). Children treated
with guanfacine showed a 43.6% decline in their ABC- hyperactivity subscale score compared
with only a 13.2% decline seen with placebo treatment (p<.001). 50% of participants were
deemed responders to the active medication of guanfacine, versus only 9.4% were responders to
placebo (p=.0001) (Scahil et al., 2015).
This study is reliable in the fact that it was a double-blinded, placebo-controlled trial. The
limited subject group provides some room for error. Although the group size was larger than
most of the similar trials reviewed, it was not large enough to be able to identify specific
characteristics that could have an impact on efficacy. The study was also done in an acute setting
and did not test the effects of extended-release guanfacine beyond 8 weeks.
Efficacy of α 2-a receptor agonists in ADHD
In a study conducted by Palumbo et al. (2008), children ages 7-12 years old that had a
diagnosis of ADHD according to DSM-IV were included. This was an 8-week trial that was
conducted at 4 sites. Subjects were randomized to either receive clonidine alone, MPH alone,
Clonidine in combination with MPH or placebo. The treatments were blinded to the subjects and
the investigators. 122 subjects were enrolled between October 2000 and April 2004. Due to the
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nature of the subject, the results of the clonidine only versus placebo were analyzed. It was found
that there was a statistically significant improvement in subjects that received clonidine versus
no clonidine. According to the CTQ, there was not a statistically significant in either the
clonidine vs no clonidine, or the clonidine vs placebo group (p=.19 and p=.52, respectively).
There was, however, a statistically significant improvement found according to CPQ both in the
clonidine vs no clonidine and clonidine vs placebo groups (p=.003 and p=.01, respectively). The
finding of the CPQ questionnaire correlated with the findings of the Children’s Global
Assessment Scale (CGAS). Improvement was shown on this scale in both the clonidine vs no
clonidine group and the clonidine vs placebo group (p=.0002 and p<.0001, respectively). The
results suggest that clonidine may have a role in improving symptoms associated with ADHD
(Palumbo et al., 2008).
It should be taken into consideration that this study excluded those subjects with
comorbid diagnoses such as anxiety and mood disorders. These are not uncommon in clinical
practice and thus these findings cannot necessarily direct clinical practice in the population with
these comorbid diagnoses. This was also a considerably short trial, and it should be kept in mind
that although clonidine may show some benefit in the acute treatment, the long-term benefit was
not tested in this trial
In a study conducted by Jain, Segal, Kollins and Khayrallah (2011) the efficacy of
Clonidine Extended Release (CLON-XR) was evaluated for the treatments of ADHD symptoms.
This included 230 subjects with ADHD diagnosis according to DSM-IV criteria. This trial was a
multisite, randomized, double-blind, placebo-controlled study. Assessments were done at
baseline, and then a 1-2-week washout period was conducted prior to medication initiation to
ensure no other medications were involved in the study. Significant improvement was shown
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throughout all doses of the active medication of CLON-XR over placebo according to the
ADHD-RS(p>.001), CGI-I (p<.0032), and Conners’ Parent Rating Scale (CPRS-R) (p<.0122)
over the 8-week study (Jain, Segal, Kollins, & Khayrallah, 2011).
It should be taken into consideration with this study that the clinicians did not titrate the
dose to each individual’s age or weight, and therefore better results could have been yielded if a
personalized dose was administered.
In this study conducted by Newcorn et al. (2013), 333 subjects with a diagnosis of
ADHD according to DSM-IV-TR were given either active Guanfacine extended release (GXR)
in the morning or evening, or placebo. This was an 8-week study that was conducted across 47
states in the United States and Canada. At the end of week 10, it was found that subjects showed
significant improvement in ADHD-RS-IV scores in the GXR group over placebo. In comparison
with baseline, the mean ADHD-RS-IV scored declined an average of 20 points for the GXR
group compared with a decrease in only 11 points in the placebo group (p<.001). In regards to
the ADHD-RS hyperactivity/impulsivity subscale scores, the GXR was again found to be
superior in improvement of scores. The mean change from baseline across the GXR groups with
-10 points as compared with the placebo group which was -5.3 (p<.001). It was also found that
dosing of GXR in the morning was equally as effective as dosing in the evening. Overall, GXR
was found to be more effective at reducing hyperactivity and impulsivity over placebo (Newcorn
et al., 2013).
This study consisted predominantly of white males. It is safe to say that these results may
not extend to clinical application through all ethnicities and genders as equally as found in this
study. It was also hypothesized in this study that due to the significant somnolence experienced

PHARMACOTHERAPY FOR AUTISM

24

as a side effect that the blind may have been broken. This leads to a possibility of bias on the part
of the subject or the parents/care givers.
The study conducted by Sallee et al. (2009) included 324 subjects age 6-17 years. It was
conducted across 51 sites in the United States from March through October 2004. All subjects
had a diagnosis of ADHD according to DSM-IV-TR criteria, and subjects with comorbid
psychiatric diagnosis were excluded. Prior to randomization, all subjects underwent a one-week
washout period, or for a time that was at least 5 times the half-life of their current medication.
They were then randomized to receive either GXR (1, 2 or 3mg dose) or placebo. According to
ADHD-RS-IV scores, all subjects receiving active GXR showed statistically significant
improvement. The mean decrease in scores from baseline to endpoint for all GXR dosing was 19.6. In comparison, the mean decrease in scores in the placebo group was -12.2. There was also
shown to be an improvement on the hyperactivity/impulsivity symptoms on all doses of GXR
over placebo. Changes in these scores were -2.7 for 1 mg (p = .028), -2.5 for 2 mg (p = .03), -3.9
for 3 mg (p = .001), and 4 mg (p = .0008). According to CGI-I scores that were completed by
investigators, 30% of subjects showed improvement with placebo, 54% with GXR-1 mg, 43%
with GXR-2 mg, 55% with GXR-3 mg, and 56% with GXR-4 mg. There was a statistically
significant improvement with GXR 1 mg, 3 mg and 4 mg dosing over placebo (p = .007, p =
.002, p = .0063, respectively). There was not a statistically significant improvement in the GXR
2mg dose over placebo (.4982) (Sallee et al.,2009).
This study was done in a fixed-dose fashion. This limited the ability to titrate dosage
according to subjects’ response and/or adverse effects. This also limited the ability of the study
to fully explore if “non-responders” would have responded at a different dose of GXR. There
was also no data collected from teachers. This limited the evaluations to be done solely outside
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of the academic world. No information on the effectiveness of GXR in the classroom setting was
obtained. This was a small time-frame of only 9-weeks. This limited the ability of this trial to
evaluate long-term effectiveness of GXR on ADHD symptoms.
The study be Wilens et al. (2015) evaluated the efficacy of GXR in adolescents that had a
diagnosis of ADHD according to DSM-IV-TR criteria. 314 children age 13-17 were included in
this trial. It was conducted in 48 centers. These subjects were randomized to receive either active
GXR or placebo between September 2011 and May 2013. This study included five periods. The
first was a 7-week dose optimization period in which the optimal dose for each subject was
investigated. This was then followed by a 6-week maintenance period and then a 2-week
medication taper. It was found that there was a statistically significant improvement of GXR vs
placebo according to ADHD-RS-IV scores by the end of the maintenance period of the trial (p <
.001). ADHD-RS-IV scores also indicated that 74.8% of the GXR group were deemed as
responders compared to 56.6% of the placebo group (p < .001). moreover, more subjects in the
GXR group (20.6%) showed improvement in their CGI-S scores as compared with placebo
(36.1%) (p = .01).
The limitations of this trial are like those discussed in previous trials. First, there were no
teacher evaluations done. This is significant because predominantly ADHD symptoms are more
readily identified in an academic setting. These symptoms also tend to inhibit daily activities in
school as well. There could have also been a potential unblinding of the experiment in that there
were no outside clinicians conducting evaluations, thus the evaluations done by the trial
clinicians could have let to unblinding as they were familiar with typical medication side effects.
Also, like other similar trials, subjects were excluded if they had any psychiatric or medical
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comorbid disorder, thus making the information gleaned from this trial less likely to be
applicable to clinical practice.
Causes for discontinuation of pharmacotherapy with methylphenidate in the treatment of
ASD
This was another study conducted by Quintana et al. (1995). This study had similar
findings as the one previously discussed by Birmaher et al. (1988). There were no statistically
significant side effects found when comparing MPH to placebo. During the high dose of MPH,
the most commonly reported adverse effect was lack of appetite at 20% of participants. There
was no CI or p value given in association with the comparison of side effect prevalence in MPH
vs placebo (Quintana et al., 1995)
In this study by Handen, Johnson and Lubetsky (2000), adverse events were more
prevalent than in the study by Birmaher et al. (1988). Adverse events were reported in both the
0.3 mg/kg and the 0.6 mg/kg doses. In relation to the 0.3 mg/kg and 0.6 mg/kg dose, the most
commonly reported adverse events were social withdrawal (54.5% and 50%, respectively),
irritability (54.5% and 70%, respectively) and poor appetite (72.7% and 70% respectively). Some
of the side effects that caused discontinuation of the medication therapy were crying, tantrums,
aggression and skin picking. Three of the thirteen children that participated in this study
discontinued early due to adverse side effect. Two of the three experienced these side effects at
the higher 0.6 mg/kg dose, requiring a dose reduction. The other child experienced severe side
effects at the lower 0.3 mg/kg dose and were therefore never given the higher dose of
methylphenidate. In total, three of the thirteen (23%) participants discontinued the study due to
adverse events (Handen, Johnson & Lubetsky, 2000).
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According to RUPP (2005), it was found that MPH is not only less effective in children
with PDD but was also associated with higher rates of adverse events than in children with
ADHD. Irritability was found to be a frequent reason for discontinuation of MPH among the
population of subjects with PDD. Other more frequent side effects associated with MPH over
placebo were decreased appetite, difficulty falling asleep, and emotional outbursts. Thirteen
(18%) of the 72 subjects discontinued the trial due to adverse effects. Six of these exited during
the test dose phase prior to the double-blind phase (RUPP, 2005).
Causes for discontinuation of pharmacotherapy with methylphenidate in ADHD
In the study completed by Greenhill, Findling and Swanson (2002), side effects were
determined by the Pittsburgh 11-item side-effect questionnaire completed by parents on same
day they completed the CGI-P. Teachers also filled out the same questionnaire with the
exclusion of sleep related questions three times per week on the same school day that they filled
out the CGI-T. At least one side effect was reported in 52% of the MPH group, and 38% in the
placebo group (p = .014). Most common adverse events were headache, anorexia, abdominal
pain, and insomnia. Of these side effects, anorexia was the only adverse event that occurred at a
statistically significant higher rate than placebo (p = .007). Of the children in the study, two
discontinued the treatment due to adverse events. One discontinued due to development of a
peri-umbilical rash. The other was due to headaches, dizziness and stomachache. No life
threatening adverse events were reported during this study (Greenhill, Findling & Swanson,
2002).
Most commonly reported side effects during the trial conducted by Wilens et al. (2006)
were headache (25%), decreased appetite (21%), insomnia (15%), and abdominal pain (9%). Of
the 177 subjects that were randomized into the double-blind phase, 18% receiving MPH and
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16% receiving placebo reported at least one adverse event. There was one serious adverse event
requiring discontinuation in which a subject threatened suicide. This patient had a history of
depression and it was thought unlikely that the suicidal ideation was a result of the MPH. Aside
from this one discontinuation, there were no other reports of discontinuation while receiving
active MPH due to side effects (Wilens et al., 2006).
Like previous studies discussed, the trial conducted by Pliszka et. al (2017) concluded
that the most common side effects related to MPH were insomnia (33.3%), decreased appetite
(18.5), and headache (7.4%). Whereas with placebo, 11.3% reported insomnia, 3.8% reported
decreased appetite, and 3.8% reported headache. There was one reported discontinuation of
MPH due to mood swings. 89.7% of sleep related adverse event were self-resolving. However,
four of the participants had their doses decreased due to sleep related issues. No serious adverse
events were reported during this trial (Pliszka et. al., 2017).
Causes for discontinuation of pharmacotherapy with α 2-a receptor agonists in ASD.
Overall, transdermal clonidine was very well tolerated with minimal side effects
according to Fankhauser et al. (1992). Of the nine participants, only one discontinued the trial
due to excessive sedation as an adverse effect. Clonidine frequently produced sedation and
fatigue as a side effect. However, after the first two weeks of active treatment the sedation was
minimal. Therefore, gradual titration of initial therapy is recommended to reduce the effects of
over sedation. Furthermore, there was found to be a statistically significant decrease in systolic
blood pressure during the 4-week active medication phase with clonidine. However, none of the
subjects reported hypotensive symptoms during the active medication phase (Fankhauser et al.,
1992).
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According to Jaselskis et al. (1992), significant increase in drowsiness and decreased
activity were noticed with clonidine vs placebo treatment. There was also significant decrease in
blood pressure in two of the subjects. With both subjects that experienced decline in blood
pressure, clonidine doses were reduced. One of the two subjects had an improvement in blood
pressure after dose reduction. The other had a continued low blood pressure of 88/50.
Drowsiness was also reported. One subject had a dose reduction due to onset of sleep one hour
after each dose of 0.025mg clonidine. Dose reduction to 0.0125mg three times daily resulted in
drowsiness subsiding. No reported incidences of headaches or stomachaches were present. Both
teachers and parents reported drowsiness and decreased activity as a significant adverse side
effect with clonidine. None of the subjects discontinued use of clonidine during the trial due to
adverse side effects (Jaselskis, Cook, Fletcher & Leventhal, 1992).
Guanfacine was very well tolerated in the study conducted by Posey et al. (2004). The
most frequently reported side effect was sedation (31.3%), however, this was not severe enough
to warrant discontinuation and appeared to be transient. The other reported adverse effects
included irritability (6.3%), constipation (3.8%), headaches (2.5%) and nocturnal enuresis 2.5%).
In no case did these side effects lead to discontinuation of the medication therapy in this study.
Blood pressure and heart rate were monitored. Change in these values were found to be clinically
insignificant (Posey, Puntney, Sasher, Kem & Mcdougle, 2004).
As with previous studies discussed, this study of guanfacine by Scahill et al. (2006),
sedation was the most notable adverse side effect (28%). Some of the other commonly reported
side effects were irritability (28%), and sleep disturbances (24%). Irritability also appeared to be
dose related, as of the seven who reported irritability, a dose reduction resulted in resolution. One
case of irritability was self-limited, while three other subjects discontinued the trial due to this
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side effect. There was a modest decrease in systolic blood pressure, but this appeared to correct
by the end of the study. Diastolic blood pressure was stable. None of the subjects discontinued
due to sedation, however, three withdrew due to irritability, and one withdrew due to perceptual
disturbance with agitation. In total, 16% of subjects withdrew due to adverse effects (Scahill et
al., 2006).
According to Handen, et al. (2008), the most common side effects in the use of
guanfacine as treatment for inattention and overactivity in children with autism were drowsiness
and lethargy. Three of the 11 subjects were unable to tolerate the full titration up to the
maximum dose of guanfacine of 3 mg/day due to adverse side effects. One subject reported
lethargy/drowsiness as an adverse effect. Another subject had to stop the titration to increased
dose due to irritability. No specific reason was given why the third participant stopped titration.
Overall it was found that all 11 children in this trial tolerated the doses of guanfacine well
without significant adverse side effects. None of the subjects discontinued the trial in relation to
side effects (Handen, Sahl, & Harden, 2008).
In the trial conducted by Scahill et al., (2015) the most common adverse effects
associated with extended-release guanfacine in this trial were drowsiness (86.7%), fatigue
(63.3%), emotional fragility and tearfulness (40%), and irritability (36.7%). Of the 62 subjects
in this trial, 30 were treated with extended-release guanfacine. Of these 30, four dropped out of
the trial. Two dropped out due to multiple adverse side effects (drowsiness, fatigue, mid-sleep
awakening, and emotional lability). The remaining two left the trial due to ineffectiveness. There
was one subject that dropped after six days of being treated with extended-release guanfacine
due to becoming verbally and physically combative and requiring inpatient psychiatric services
for three days. Nine of the 30 subjects receiving the active medication dose had to have their
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dose reduced due to unwanted adverse events (i.e. drowsiness, tearful/emotional presentation,
irritability, and/or lowered blood pressure). Of the 32 subjects receiving placebo medication, five
had their dose reduced due to similar complaints (Scahill, et al., 2015).
Causes for discontinuation of pharmacotherapy with α 2-a receptor agonists in ADHD.
Side effects associated with Clonidine in the treatment of ADHD are like the side effects
reported in the treatment of ASD. Somnolence and fatigue were the most common side effects
that led to discontinuation of pharmacotherapy. In the study conducted by Jain, et al. (2011),
83% of the subjects receiving active CLON-XR medication reported adverse effects, whereas
72% of people receiving placebo reported adverse effects. Most of these were mild to moderate
in severity. After investigator review, it was found that 45%, 70% and 62% of the adverse effects
in placebo, CLON-XR 0.2mg/day and CLON-XR 0.4mg/day, respectively, were related to
treatment. Discontinuation rates due to adverse effects were 1% in placebo group, 7% in the
CLON-XR 0.2mg/day group, and 19% in the CLON-XR 0.4mg/day group. In the CLON-XR
0.2mg/day group, 4% discontinued due to somnolence and 3% discontinued due to fatigue. (See
Table 1.) In the CLON-XR 0.4mg/day group, 6% discontinued due to somnolence, 5%
discontinued due to fatigue, and 4% discontinued due to other reasons to include formication
(1%), prolonged QT interval (1%), rash (1%) and vomiting (1%). Discontinuations due to
reported lack of efficacy were 32% in placebo, 9% in 0.2mg CXR, and 11% in 0.4mg CXR.
There were no life-threatening emergent effects or deaths reports during this trial (Jain, Segal,
Kollins, & Khayrallah, 2011).
The article by Daviss et al. (2008) is a companion article to the trial conducted by
Palumbo et al. in which efficacy of clonidine, MPH and a combination dosing was evaluated in
the treatment of ADHD. This companion article focuses on the side effects associated with the
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use of clonidine alone, MPH alone, and MPH in conjunction with clonidine. The Pittsburgh Side
Effect Scale for teachers and parents were used to evaluate reported side effects. Subjects treated
with clonidine were found to have a significantly higher rate of adverse effects than those not
treated with clonidine (p < .0001). Of these adverse events, fatigue and nervousness were more
frequently reported in the clonidine group as well (p = .03 and p = .04, respectively). Despite
these higher incidences of reported side effects, the discontinuation rate of subjects treated with
clonidine was lower than those that did not receive clonidine (p < .0001). One discontinuation of
clonidine was due to social withdrawal and sedation, while another was due to a 10-pound
weight gain. The most commonly reported adverse events were dull/tired/listless,
drowsiness/sedation, and crabby/irritably as reported by parents and teachers (Daviss et al.,
2008).
In a study conducted by Sallee et al., (2009), the most common adverse effects of
somnolence, sedation and fatigue were self-limiting and resolved by the end of the study. The
rate of discontinuation due to somnolence, sedation and fatigue were n = 8 for the active GXR
group, and n = 5 for the placebo group. The total rate of discontinuation due to side effects in this
trial were GXR of 7.4% and placebo at 7.6%. The overall incidence of reported adverse effects
were similar in both the GXR group (74%) the placebo group (76%). Although, incidences of
somnolence, headache and fatigue were all greater in the GXR (27%, 21% and 9% respectively
compared to the placebo group (12%, 11% and 3%, respectively). GXR was not associated with
any statistically significant changes in weight, lab values, EKG readings, blood pressure or heart
rate (Sallee et al., 2009).
As with previous similar studies, the most frequently reported adverse effects according
to Newcorn et al. (2013) were mild (36.7%) to moderate (40.7%) in severity in subjects taking
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GXR. Nine of the subjects (4.1%) reported severe side effects. Two were related to
mild/moderate syncopal episodes and one was due to suicidal ideation. Each of the three
subjects were taken off the active GXR dose and symptoms resolved. The top three most
frequently reported side effects in those taking the active GXR dose were somnolence (44.3%),
headache (16.7) and sedation (14.5%). The incidence of discontinuation due to somnolence,
sedation and hypersomnia were 4.1% in the GXR group and 0% in the placebo group indicating
a more significant effect in the active medication group. Although these side effects were more
frequently reported in the GXR group, most of these effects resolved (78.1%) before the taper
period of the trial (Newcorn et al., 2013). These findings correlate with the previous study
discussed by Sallee et al., (2009).
A study conducted by Wilens et al., 2015 reported similar adverse effects as that shown
in the studies previously discussed by Sallee et al., (2009) and Newcorn et al., (2013).
Somnolence, headache and fatigue were the most frequently reported side effects in this trial in
which GXR was compared to placebo. A total of 93.6% of subjects in the GXR group and 77.4%
in the placebo group reports experiencing at least one treatment related side effect during the
study. Of these reported, the most common were somnolence (43.9% and 21.3%, respectively),
headache (26.8% and 18.1%, respectively) and fatigue (22.3% and 12.3%, respectively). As with
the previously discussed studies, the severity of these side effects was reported as mild/moderate,
most of these symptoms resolved prior to the end of the study (GXR: 78.9% and placebo:
57.1%). There were nine participants that ultimately withdrew from the study due to adverse
effects. Fatigue was reported by two participants. Three of those that withdrew did so due to
experiencing more than one side effect. These included: homicidal ideation, irritability, WolfParkinson-White syndrome, diarrhea, headache, nausea, unrelated bradycardia, hypotension,
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dizziness, constipation and postural dizziness. All symptoms except hypotension and vomiting
were found by clinicians to be unrelated to the medication. There was no incidence of medication
related discontinuation of the placebo group.
Discussion
In children with ASD, are psychostimulants such as methylphenidate as effective at
reducing impulsivity-hyperactivity behaviors when compared to children with ADHD
according to teacher and parent reports?
According to the review of literature, it was found that MPH was statistically significant
at reducing impulsivity-hyperactivity in both children diagnosed with ASD as well as ADHD
across the studies evaluated. For example, studies conducted with children with ASD were often
limited in numbers of participants. The number of subjects in the ASD studies ranged from 9-13
compared to the ADHD studies which ranged from 220-314. The response rate to MPH in the
ASD group ranged from 49-61%, whereas, responders in the ADHD population ranged from 5281%. These were according to CGI Global improvement and Conners’ Hyperactivity Index. Due
to the limited studies that evaluate efficacy in children with ASD, as well as variations of tools
used to assess behaviors, it is inconclusive as to which population responds better to treatment
with MPH. Although one could possibly glean that MPH is slightly more effective at treating
hyperactivity-impulsivity in the ADHD population vs ASD when looking at response rates.
Further investigation will need to be done with larger numbers of participants as well as a
standardized method of evaluation.
In children with ASD, are α 2-a adrenergic receptor agonists, such as clonidine and
guanfacine, more effective at reducing impulsivity-hyperactivity behaviors as compared to
psychostimulants such as methylphenidate, according to teacher and parent reports?
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Overall, MPH and α 2-a adrenergic receptor agonists were both found to be statistically
significant at modifying impulsivity-hyperactivity behavior in children with Autism. When
comparing results among studies, it is hard to compare efficacy as the tools of measurement
differed between studies. In the study conducted by Quintana and Birmaher (1995), MPH was
found to be statistically significant over Placebo (PBO) according to CTQ. However, CPQ
results did not show any significant improvement in MPH over PBO. The study by Handen et al.
(2000) showed that 61.5% of the test subjects responded to MPH. Moreover, eight of 13
participants had a minimum decrease of at least 50% on the Teacher Conners Hyperactivity
Index. In the study by RUPP (2005), 35 of the 72 (49%) subjects responded to MPH. This was
based off a score of “much improved” or “very much improved” on the CGI scores. In looking at
these three studies, one found no improvement over PBO, another found that 49% of subjects
were responders, and the third found 61.5% to be responders. With such a vast range of subjects
finding benefit with MPH, it is unclear as to the overall efficacy of MPH in the ASD population.
In studies conducted by Fankauser et al. (1992), Posey et al. (2004) and Scahill et al.
(2015), subjects were found to be “much improved” or “very much improved” according to CGI
scores in 66.7%, 23.8% and 50% (respectively) when taking active α 2-a adrenergic receptor
agonists such as guanfacine and clonidine. This is similar, however slightly higher in percentage
than the 49% of responders to MPH in the study by Handen et al. (2000) suggesting that more
improvement was seen in α 2-a adrenergic receptor agonists over MPH according to CGI scores.
Are the rates of discontinuation of pharmacotherapy in children with ASD higher in
treatment with MPH vs clonidine or guanfacine?
In the studies conducted by Quintana et al. (1995), there was very little incidence of
significant adverse effects reported by participants taking MPH. There were also no reported
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discontinuations of pharmacotherapy with MPH in this trial. This is in stark contrast to the trials
by RUPP (2005) and Handen et al. (2000) in which 18% and 23% of subjects, respectively,
discontinued the trial due to significant side effects. These differing results in studies could be
due to the evolving definition of Autism between DSM-III which was used in the trial by
Quintana (1995) and the DSM IV which was used for both trials conducted by RUPP (2005) and
Handen et al. (2000). The most frequently reported side effects were lack of appetite, social
withdrawal, irritability and aggression. Lack of appetite was the most commonly reported,
ranging from 20%-72.7% of subjects across the studies reviewed. Although most common, this
was not a reported reason for discontinuation of medication therapy. The most common reasons
for discontinuation were irritability, crying, tantrums, skin picking and aggression. Of the two
studies that reported significant side effects, the rates of discontinuation due to these adverse
events ranged from 18-23% of subjects, while one study showed no significant side effects and
had no reports of discontinuation due to adverse events.
With α 2-a adrenergic receptor agonist use, the most commonly reported adverse events
were somnolence and fatigue. Of the five trials that were reviewed, two reported no incidence of
discontinuation due the adverse events. Of the three trials that did report discontinuation due to
side effects, these rates ranged from 6-16% of subjects. The most common reasons for these
discontinuations were due to excessive fatigue, somnolence, irritability and emotional lability.
When comparing the trials, it was found that MPH had slightly higher rates of discontinuation
then α 2-a adrenergic receptor agonists with 18-23% of discontinuations with MPH, and 6-16%
with α 2-a adrenergic receptor agonists. It must be taken into consideration that these trials were
conducted over a 30-year time span, and the subject groups were relatively small. To validate the
results of these trials, additional studies with larger subject sizes should be conducted.
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Conclusion
After reviewing the literature, it was found that both MPH and 2-a adrenergic receptor
agonist have a potential role in pharmacotherapy for ASD. MPH may be slightly more effective
at reducing hyperactivity-impulsivity behaviors than 2-a adrenergic receptor agonist, however
the side effect profile in MPH has led to more discontinuations over 2-a adrenergic receptor
agonist. Although MPH might be more effective, it could be outweighed by the increased
incidence of adverse events, thus resulting in less adherence to medication therapy. More studies
would need to be conducted to validate the findings of this review.
Application to Clinical Practice
Behaviors associated with Autism such as hyperactivity and impulsivity are often
detrimental in various situations of life. According to Baio et al. (2014), the incidence of Autism
Spectrum Disorder in 8-year old children is 1 in 59. This increased from approximately 1 in 150
reported in 2000-2002 (Baio et al., 2014). The increasing incidence of autism is evidence that
continued investigation and evaluation of the most efficacious medical management is needed to
meet the needs of this increasing population. By identifying the most efficient pharmacological
therapy for these behaviors, providers can help to prescribe an appropriate medication regimen to
improve quality of life for both patients and caregivers. This scholarly project will help providers
to navigate not only the most effective pharmacotherapy, but also increase adherence to
medication by recognizing the most common side effects leading to medication discontinuation
by families.
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Table 1.
Rate of somnolence and fatigue according to CLON-XR dose
Adverse Effect

CLON-XR 0.2mg/day
n=76
18%

CLON-XR 0.4mg/day
n=78
10%

21%

14%

0

6%

Mild Fatigue

13%

4%

Moderate Fatigue

1%

8%

Severe Fatigue

1%

1%

Mild somnolence
Moderate somnolence
Severe somnolence

Note. Adapted from Jain et al. (2011).

